Effect of FPP on Cutaneous Barrier Integrity

Inclusion criteria

• 50-75 years
• Willing to allow collection of 3 blood samples (Baseline, Week 12 and Week 20)
• Willing to log daily compliance with FPP intake during the study period (12 weeks)
• Absence of active systemic disease per investigator judgement.
• No current use of immunosuppressant or immunomodulatory medications.
• No active dermatological conditions at measurement sites that could impair measure, per investigator judgement.
• Investigator determination of general good health.

Exclusion criteria

• Co-morbidity or concurrent medication that the Investigator deems impactful to patient safety or ability to adhere to FPP dosage.
• Co-morbidity or concurrent medication that the Investigator deems confounding to outcome measure (i.e., topical or systemic steroid).
• Current or history of allergy to FPP ingredients: Dextrose, Carica papaya, or Food yeast.
• Concurrent participation in another interventional trial that may impact measures, per investigator judgement.
• Uncontrolled diabetes (A1c >7%).
• Open wounds or actively receiving Wound Care services.
• Pregnant or breastfeeding women.
• Current use of warfarin.